Day: December 2, 2025

New award expands Gilat Defense’s portfolio of advanced capabilities PETAH TIKVA, Israel, Dec. 02, 2025 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions, and services, announced today that Gilat DataPath has been selected to deliver a customized Earth Observation Solution. The order, valued at approximately $10 million, will be delivered within the next 12 months. This award reflects the continued expansion of Gilat Defense’s portfolio of specialized capabilities beyond satellite communications and into the earth observation and geospatial insights domain. The tailored solution leverages satellites equipped with various sensors to provide real-time data for intelligence, surveillance, reconnaissance, and situational awareness. The capability...

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) — Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the Evercore 8th Annual Healthcare Conference on Thursday in Miami. Evercore 8th Annual Healthcare ConferenceDecember 4, 202510:50 a.m. ET – fireside chat A simultaneous webcast of the event will be available on the Investors section of Nkarta’s website, and a replay will be archived on the website for approximately 90 days. About NkartaNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for autoimmune diseases. By combining its cell expansion and cryopreservation platform with proprietary...

Strengthening our Advisory Board with addition of Mark McKenna as Strategic Advisor and Peter Libby, MD as a Clinical AdvisorExpanding the Phase 2 recurrent pericarditis study into Canada, EU and the UK to evaluate QD dose ranging in preparation for the global Phase 3 development planInterim analysis for the ongoing Phase 2 recurrent pericarditis study to now be presented as part of Ventyx’s R&D Day planned for Q1 2026SAN DIEGO, Dec. 02, 2025 (GLOBE NEWSWIRE) — Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammation-mediated cardiovascular and neurodegenerative diseases, today announced that the Company added two leading experts to their advisory board and provided an update to its ongoing...

– Study, Which Enrolled 27 Patients, Met Primary Endpoint with a Significant Reduction in Hearing Loss in 3-18 Year Old Patients who Received PEDMARK® when Compared with Historically Reported Rates of Hearing Loss in Patients Receiving Cisplatin Alone (16-24% versus 56-63%, Respectively) – – PEDMARK® Showed No Interference with Cisplatin Antitumor Activity as Evidenced by an Approximate 95% Clinical Response Rate – – The Company Plans to Pursue Registration and is Exploring Partnering or Licensing Opportunities for PEDMARK® in Japan Based Upon These Results – RESEARCH TRIANGLE PARK, N.C., Dec. 02, 2025 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced positive topline results from the investigator-initiated Phase 2/3 STS-J01 clinical trial evaluating PEDMARK®...

Streamlined workflows and enhanced developer experience drive revenue growth for the most trusted source of weather forecasts and warnings with proven Superior Accuracy™ CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) — Akamai Technologies, Inc. (NASDAQ: AKAM), the cybersecurity and cloud computing company that powers and protects business online, today announced a partnership with Zuplo that is transforming how AccuWeather®, the most trusted source of weather forecasts and warnings with proven Superior Accuracy™, delivers and monetizes its APIs. By combining Akamai’s global edge platform with Zuplo’s modern API gateway, AccuWeather is simplifying API management, enhancing the developer experience, and unlocking new revenue opportunities. Together, Akamai and Zuplo deliver a modern API platform designed for scale...

ST. JOHN’S, Newfoundland and Labrador, Dec. 02, 2025 (GLOBE NEWSWIRE) — Kraken Robotics Inc. (“Kraken” or the “Company”) (TSX-V: PNG, OTCQB: KRKNF) announces it has received purchase orders for synthetic aperture sonar (SAS) and battery products totaling approximately $12 million. Orders for Kraken SAS, KATFISH™ towed SAS spares, and SeaPower™ batteries have been placed by multiple organizations, including Teledyne Marine, Terradepth, and two navies from NATO member countries. “As we near the end of the calendar year, we are seeing many expected orders coming through before budgets reset, including two new SeaPower battery customers” said Greg Reid, President and CEO of Kraken Robotics. “Clients are from both defence and commercial organizations, highlighting how Kraken’s dual-use technology is critical across a variety...

Expert retina and uveitis specialists will help support the growth and innovation of ANI’s ophthalmology and retina franchise for a meaningful impact on patients PRINCETON, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) — ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that it has established The FutureVision Advisory Council to help guide the strategic advancement of its ophthalmology and retina franchise within the Company’s Rare Disease business. This steering committee includes seven retina specialists and three uveitis specialists recognized globally as leaders in their respective fields. “We have built a strong foundation for our ophthalmology and retina franchise and continue to look for opportunities to further positively impact patients,” said Nikhil Lalwani, President and Chief Executive Officer...